It will also be important to test the binding ability of the human NKG2D-Fc-IL2 to different human cancer cell lines, as well as characterize the functionality of the IL-2 component before considering the generation of a clinical grade reagent for clinical trials. The gene discussed is KLRK1; the disease is cancer.